علاج التهاب رئة كوفيد-19 الشديد غير الحرج في المرضى المستشفيين (SpO2 ≤94%)

References

Among hospitalized patients with severe, but noncritical, COVID-19, the IDSA guideline panel suggests dexamethasone rather than no dexamethasone.

Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen.

Among hospitalized adults with progressive severe or critical COVID-19 who have elevated markers of systemic inflammation, the IDSA guideline panel suggests tocilizumab in addition to standard of care (ie, steroids) rather than standard of care alone.

When tocilizumab is not available, for patients who would otherwise qualify for tocilizumab, the IDSA guideline panel suggests sarilumab in addition to standard of care (ie, steroids) rather than standard of care alone.

Among hospitalized adults with severe COVID-19, the IDSA panel suggests baricitinib with corticosteroids rather than no baricitinib.

Among hospitalized adults with severe COVID-19 but not on noninvasive or invasive mechanical ventilation, the IDSA panel suggests tofacitinib rather than no tofacitinib.